tradingkey.logo
tradingkey.logo
Suchen

Exact Sciences Corp

EXAS
Zur Watchlist hinzufügen
104.910USD
0.0000.00%
Handelsschluss 06/29, 16:00ETKurse um 15 Minuten verzögert
20.03BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Exact Sciences Corp Unternehmen

Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Exact Sciences Corp Informationen

BörsenkürzelEXAS
Name des UnternehmensExact Sciences Corp
IPO-datumJan 30, 2001
CEOConroy (Kevin T)
Anzahl der mitarbeiter6900
WertpapierartOrdinary Share
GeschäftsjahresendeJan 30
Addresse5505 Endeavor Lane
StadtMADISON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl53719
Telefon16082845700
Websitehttps://www.exactsciences.com/
BörsenkürzelEXAS
IPO-datumJan 30, 2001
CEOConroy (Kevin T)

Führungskräfte von Exact Sciences Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%
Mr. James E. Doyle
Mr. James E. Doyle
Lead Independent Director
Lead Independent Director
--
--
Mr. D. Scott Coward
Mr. D. Scott Coward
Director
Director
--
--
Mr. Jacob (Jake) Orville
Mr. Jacob (Jake) Orville
Executive Vice President, General Manager - Screening
Executive Vice President, General Manager - Screening
--
--
Mr. Paul Clancy
Mr. Paul Clancy
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kevin T. Conroy
Mr. Kevin T. Conroy
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
279.16K
-457.95%
Mr. Daniel J. (Dan) Levangie
Mr. Daniel J. (Dan) Levangie
Independent Director
Independent Director
34.31K
+15.73%
Ms. Shacey Petrovic
Ms. Shacey Petrovic
Independent Director
Independent Director
7.09K
-307.32%
Mr. Brian Baranick
Mr. Brian Baranick
Executive Vice President, General Manager - Precision Oncology
Executive Vice President, General Manager - Precision Oncology
670.00
-15503.58%
Mr. Aaron Bloomer
Mr. Aaron Bloomer
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
212.00
-23003.77%
Ms. Katherine S. (Kay) Zanotti
Ms. Katherine S. (Kay) Zanotti
Independent Director
Independent Director
--
-100.00%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Exact Sciences Corp?

Die fünf größten Anteilseigner von Exact Sciences Corp sind: Mr. Kevin T. Conroy

Wie viele Institutionen halten Anteile an Exact Sciences Corp (EXAS)?

Mit Stand vom 2026Q1 halten 1452 Institutionen Anteile an Exact Sciences Corp, mit einem Gesamtmarktwert von etwa 147.12M, was 77.07% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -48700001.00 gestiegen.

Was ist die größte Einnahmequelle von Exact Sciences Corp?

Am 2026Q1 erzielte das Geschäft mit Commercial für Exact Sciences Corp den höchsten Umsatz in Höhe von 1.52B, was 46.79% des Gesamtumsatzes entspricht.
KeyAI